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ing by ElAbstract Background: Microwave ablation (MWA) is a new treatment modality for hepatocellu-
lar carcinoma (HCC) at our institution. The aim of this study is to evaluate the safety, procedure
time and rate of complete ablation of this new modality.
Material and methods: Hospital medical ethics committee approval and informed consent were
obtained. A total of 98 nodules in 72 patients (59 male, 13 female; mean age 57 (±4.6) years, range
50–70 years) with HCC were treated with microwave ablation at our institution from June 2010 to
February 2011. A 14 G cooled shaft Amica probe was introduced into the tumors under analgesic
sedation and by US guidance. The patients were then followed up with contrast enhanced computed
tomography (CT) and serum a-fetoprotein levels.
Results: One month after therapy, complete ablation was obtained in 96% (94/98) nodules. The
complete ablation rate in tumors 63 cm and those >3 cm were 98%, and 94%, respectively.
MW ablation success was higher with nodules 63 cm (57/58, 98.3%) in comparison to nodules(O.M. Hetta), naglaashebrya
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344 O.M. Hetta et al.>3 cm (37/40, 92.5%): however, the difference was non-signiﬁcant (P= 0.301). No complication
occurred related to the ablation procedure, only minor complications post-ablation, as pain in
(3/72) patients, mild fever in (48/72) patients, and discharge from wound in (2/72) patients. No local
recurrence was detected, however, new lesions at other sites of the liver occurred in 11 (15%)
patients.
Conclusion: Sonographically guided percutaneous microwave ablation proved to be safe, fast, and
effective for treatment of hepatocellular carcinoma.
 2011 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
All rights reserved.Table 1 Demographic, clinical, and laboratory parameters of
all studied patients at study entry (pre-operative).1. Introduction
Hepatocellular carcinoma (HCC) is one of the most malignant
tumors with a high mortality, aggressive growth behavior and
a high recurrence rate (1). Hepatocellular carcinoma usually
develops following chronic liver inﬂammation caused by hepa-
titis C (HCV) or B (HBV) virus (1). Egypt has the highest prev-
alence of HCV in the world and up to 90% of HCC cases in
the Egyptian population were due to HCV (2). Therefore,
HCC represents an important public health problem in Egypt
and is the third among male cancers with >8000 new cases
predicted by 2012 (2).
Surgical resection has been recognized as the most poten-
tially curative treatment for patients with HCC. Unfortu-
nately, the majority of patients with primary HCC are
frequently considered unresectable because of tumor number,
location, or poor hepatic functional reserve due to underlying
liver cirrhosis/hepatitis thus making resection of large volume
of liver parenchyma unfeasible (3). Therefore, local ablative
techniques have been developed to enable local destruction
of tumors without damage of the healthy parenchyma (4).
The tumors are destroyed in situ either by direct chemical
application (ethanol ablation) or by cooling (cryotherapy) or
by heating (radiofrequency or microwave ablation) (5).
Percutaneous MWA has been recently introduced at our
institution and the aim of this study is to present our initial
experience in the use of this new microwave technology as
an alternative therapy for patients deemed inoperable for
HCC, regarding its safety, procedure time and rate of complete
ablation.Gender Male 59 (81.9%)
Female 13 (18.1%)
Age (years) 57.0 ± 4.6 (50–70) [57.5]
Child-Pugh A 24 (33.3%)
B 45 (62.5%)
C 3 (4.2%)
Ascites None 19 (26.4%)
Mild 35 (48.6%)
Severe 18 (25.0%)
Encephalopathy None 72 (100%)
Albumin (g/dL) 3.4 ± 0.6 (2.1–4.8) [3.3]
Bilirubin (mg/dL) 1.9 ± 1.6 (0.3–5.4) [1.6]
PT (s) 14.3 ± 1.8 (12–17) [14]
INR 1.1 ± 0.1 (0.9–1.3) [1.1]
PTT (s) 37.9 ± 4.6 (30–45) [39]
ALT (U/L) 51.9 ± 20.1 (13–91) [52.5]
AST (U/L) 48.0 ± 19.4 (14–81) [49.5]
Hb (g/dL) 11.4 ± 1.5 (9.0–14.0) [11.4]
TLC (·103 lL1) 7.4 ± 2.1 (3.7–11.2) [7.5]
PLT (·103 lL1) 203.1 ± 23.1 (161–240) [202.5]
Creatinine (mg/dL) 0.9 ± 0.4 (0.3–1.5) [1.0]2. Materials and methods
2.1. Patients
From June 2010 to February 2011, a total of 99 patients with
HCC, deemed unsuitable for hepatic resection were referred to
our interventional radiology department from the hepatic sur-
gery department at Ain Shams University Hospital. A total of
72 patients were recruited into this prospective study and treated
with ultrasound-guided percutaneous MWA. The study group
included 59 (81.9%) male and 13 (18.1%) female, with an aver-
age age (±SD) of 57 (±4.6) (range, 50–70 years). Exclusion cri-
teria were: age older than 80 years, evidence of extra-hepatic
metastases, more than ﬁve intra-hepatic nodules, presence of
vascular involvement or extra-hepatic metastases, and severe
bleeding diathesis (INR > 1.5) (6). The enrolled patients gave
their written informed consent to enter the study after the proce-dure of thermal ablation was explained to them. The study was
approved by the medical ethics committee of the hospital.
Diagnosis was settled by signiﬁcant elevation of a-fetopro-
tein >200 lg/L and/or typical computed tomography (CT)
criteria of HCC by triphasic spiral CT. The numbers of
patients with single tumor nodule were 46 (63.9%) and those
with two tumor nodules were 26 (36.1%). A total of 98 tumor
nodules sized 2–5 cm with an average diameter (±SD) of 3.2
(±0.9) were treated. Fifty eight (59.2%) nodules were 3 cm
or smaller and 40 (41.8%) nodules were larger than 3 cm.
Forty (55.6%) of the 72 patients had an increased serum
a-fetoprotein level (>200 lg/L). Liver function status was
classiﬁed as Child-Pugh class A in 24 patients (33.3%), B in
45 patients (62.5%), and C in 3 patients (4.2%). Standard
pre-operative evaluation of patients included a triple phase
computed tomography (CT) scan of the abdomen and pelvis,
abdominal ultrasound, laboratory investigations, including;
liver enzymes (SGOT, SGPT), serum albumin, coagulation
proﬁle (PT, PTT, INR), serum creatinine and complete blood
picture (Table 1).
2.2. Ablation procedure
Microwave ablation was performed percutaneously under
real-time ultrasound guidance using a GE LOGIQ 7 Pro US
scanner (USA) with a 3.5–5 MHz probe. The ablation proce-
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(Diprivan).
MWA was performed using as HS AMICA microwave
delivery system (HS Hospital service S.P.A Roma, Italy). This
microwave delivery system consisted of a MW generator
named AMICA Gen., operating at frequency of 2450 MHz
and a power output up to 100 W, and a 14 gauge (14G ·
150 mm and 14G · 200 mm) cooled shaft electrode named
AMICA-probe to deliver MW energy into liver tissue.
Before treatment began, a detailed plan for the placement
of the electrode, the power output setting, and the emission
time was established on a tumor-by-tumor basis. The aim of
the treatment was to completely destroy the tumor, as well
as the surrounding 0.5–1.0 cm normal appearing liver tissue.
A pre-incision of the skin is done and a 14-gauge 15 cm
guide needle with a sheath was inserted and positioned at the
designated place of the tumor under sonographic guidance,
then the stylet of the guide needle was pulled out. After the
microwave electrode was introduced through the sheath of
the guide needle, the sheath was withdrawn approximately
4–5 cm while keeping the electrode needle at its place to ensure
that a portion of at least 4 cm from the tip of the electrode was
exposed. Usually the tip of the electrode has to be placed at the
bottom of the lesion about 0.5 cm inside the tumor margin.
Being connected to the microwave generator, the energy
application was then started.
In general a high power for a low time was used, i.e., an
output setting of 60 W for 300 s. For some tumors, a pro-
longed application (300–800 s) of energy 60 W was used.
In lesions > 3 cm, after the ﬁrst application we stop the
treatment, then the needle can be just moved a bit backward,
change direction of re-insert into the tumor, and start a further
treatment session. This maneuver was repeated 2–4 times
according to the size of the lesion. This ensues a bigger dimen-
sion of necrosis than applying the microwaves for the maxi-
mum time (25 min for 60 W), since during the last 5–10 min,
the dimension of necrosis increases very slowly.
During each application of microwave energy, an expand-
ing hyperechogenic area was produced which roughly judges
the size of the ablation zone, i.e., necrotic zone. The necrosis
length overcomes the tip of the electrode ahead by few mm
(2–6 mm) depending on power and time of the treatment while
the biggest increase occurs backwards and radially as the time
goes over. These changes are visible on sonographic images
but diminished rapidly as soon as the microwave generator
was switched ‘‘off’’ and completely disappeared within 8 h.
To minimize tumor seeding, the needle track was routinely ab-
lated while withdrawing the antenna at about 2 cm/s. The
power has to be set at 40 W.
2.3. Assessment of therapeutic efﬁcacy
Local therapeutic efﬁcacy was evaluated by contrast enhanced
dynamic CT scanning (GE, Hi Speed Dual CT, USA) at
1 month after treatment. Complete ablation was deﬁned as
uniform hypo-attenuation without enhancement in the previ-
ous tumor area (7,8). However, contrast enhancement in the
ablated zone indicated incomplete ablation or local recurrence
when detected later on (9). Technical success was deﬁned as
complete ablation of the tumor, as determined at CT per-
formed 1 month after MWA (10). Thereafter, CT examina-tions were performed once every 3 months interval up to the
end of the study period.
Serum a-fetoprotein level was checked at 1 month after
MWA. If the results showed an abnormal serum a-fetoprotein,
subsequent checks were performed at an interval of 2–
3 months.
Statistical analysis of the data was performed by using
SPSS15 software package under Windows7 operating sys-
tem. Categorical data parameters were presented in the form
of frequency and percent. Quantitative data were expressed
in the form of mean, SD, range and median. Comparison
was performed by Fisher exact test for categorical data and
paired t-test for quantitative data. Probability level (P-value)
was assumed signiﬁcant if less than 0.05 and highly signiﬁcant
if P-value was less than 0.001. P-value was considered non-sig-
niﬁcant if greater than or equal to 0.05 Graphic presentation of
data was done by using SPSS15 software.
3. Results
The study included all cases referred from hepatic surgery
department between June 2010 and 28th February 2011; that
fulﬁlled the informed consent and inclusion criteria.
MW ablation was utilized to treat 98 hepatic tumor nod-
ules in 72 patients. There were 59 men and 13 women with a
mean age of 57 years (range: 50–70 years). Forty six patients
had a single tumor nodule (Figs. 1–3) while 26 patients had
two tumor nodules (Fig. 4), with a mean size of 3.2 cm.
The locations of these tumors were evenly distributed for
both the right and left lobes, with one tumor located within
the caudate.
All patients completed the procedure safely and the median
ablation time was 10 min (range: 5–15 min).
Technical success, as determined at dynamic CT performed
1 month after percutaneous MWA, was achieved in 94 (96%)
of 98 nodules. The technical success rates for tumors 3 cm or
smaller (Fig. 4) and those larger than 3 cm (Fig. 1–3) were
98.3% (57 of 58 nodules) and 92.5% (37 of 40 nodules), respec-
tively. The four incompletely ablated tumors were treated with
additional MWA sessions and technical success was achieved in
all. MW ablation success was higher with nodules 63 cm (57/
58, 98.3%) in comparison to nodules >3 cm (37/40, 92.5%):
however, the difference was non-signiﬁcant (P= 0.301).
Follow-up for all cases extended for 10 months (from the
start of the study till 31st March 2011) with a mean of
4 months (162 days ± 81); including the ﬁrst follow-up step
at 1sth month after MWA then every 3 months; accordingly
26 (36.1%) patients were followed once, 22 (30.6%) patients
were followed twice, and 24 (33.3%) patients were followed
thrice (Table 2). During this limited period, none of the
patients died, no local recurrence was detected up to the time
of writing, however, new lesions at other sites of the liver
occurred in 11 (15.3%) patients.
Alpha-fetoprotein (a-FP) was measured for all patients pre-
operatively, mean a-FP was 317.9 ± 235.1 (median = 231).
Patients with values <200 lg/L (n= 32) were excluded from
follow-up with a-FP. Those patients were only evaluated by
CT examination. Out of the 40 patients that had a-FP with
values > 200 lg/L, 39 patients showed decreased level to with-
in the normal range one month after ablation. The patient with
increased a-FP showed a signiﬁcant decrease in a-FP level at
Figure 1 Contrast-enhanced transverse CT scans in a 55-year old man with solitary HCC. (a) Pretreatment contrast enhanced scan
reveals a 3 · 5 cm enhancing HCC (arrow) in segment V. (b) Scan obtained 1 month after PMCT depicts a non-enhancing
hypoattenuating area (arrow head) with evident safety margin.
Figure 2 CT ﬁnding in 50-year old male with hepatocellular carcinoma. (a) Arterial phase CT scan obtained before microwave therapy
shows a 5 · 5 cm hypervascular hepatoma (arrow) in segment VI of liver. (b) Arterial phase CT scan obtained 1 month after microwave
therapy shows no enhancement within lesion.
Figure 3 Transverse CT images obtained in a 60-year old man with HCC treated with PMCT. (a) Pretreatment contrast enhanced image
depicts a 4 · 5 cm enhancing (arrow). (b) Contrast enhanced scan 3 months after PMCT shows a non-enhancing hypoattenuating area
(arrow).
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Figure 4 Contrast-enhanced transverse CT scan in a 45-year old man with two HCC nodules. (a) Pretreatment scan reveals a 1 · 3 cm
HCC (arrow) and 2 · 2 cm HCC (arrow head) in segment VIII and segment III, respectively. (b) Scan obtained 1 month after PMCT
depicts a non-enhancing hypoattenuating areas at previously mentioned sites of tumor nodules (arrow and arrow head).
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then it dropped to the normal level at 7 months post-ablation
(Table 2, Fig. 5).
Comparison between pre-operative versus follow-up a-feto-
protein values showed that values signiﬁcantly decline by time
(t= 11.997, 12.023, 7.541; P< 0.001 for 1 m, 4 m and 7 m
comparisons, respectively). Moreover, there was signiﬁcant de-
cline on comparing a-fetoprotein at 4 m versus that at 7 m
(t= 2.342, P= 0.036).
In our study, no complication occurred related to the abla-
tion procedure. After percutaneous MWA, three patients
whose tumors were located in the liver dome had severe right
upper quadrant pain. The pain was relieved with the oral
administration of analgesics. Forty-eight (66.6%) patients
had a mild fever, which lasted 1–3 days. In two patients, a
small discharge from the puncture wound occurred on the ini-
tial days after therapy and cleared up after local treatment. No
other clinically relevant complications were observed.
4. Discussion
With the advantages of minimal invasiveness and predictabil-
ity of therapeutic efﬁcacy, thermal ablation has quickly gained
a great deal of attention in the management of HCC (11,12).In recent years, the potential role of microwave ablation
(MWA) has become increasingly apparent, micro-wave device
and antenna had been greatly improved (13,14). In microwave
ablation an ultra-high-speed microwave (usually 2450 MHz) is
emitted from exposed antenna of the electrode, causing the
water molecules in the tissue to vibrate and rotate with similar
frequency. Heat is generated and results in thermal coagula-
tion of the target tissue (6).
In this study, a 2450 MHz internally cooled-shaft antenna
was used. It has two channels inside the shaft lumen with dis-
tilled water circulated by a peristaltic pump to continuously
cool the shaft. The low antenna shaft temperature can deliver
more energy into the tissue without causing skin burn. In addi-
tion, low antenna shaft temperature can reduce higher temper-
ature in the center to decrease tissue charring and improve
energy transfer, which makes possible higher output and long-
er duration treatment (15). As result, the ablation zone can be
remarkably expanded.
Microwave ablation can be performed percutaneously, lap-
aroscopically, thoracoscopically, or at laparotomy. Percutane-
ous treatment offers several advantages over other approaches
(16). The percutaneous approach is the least invasive, relatively
expensive, can be performed on outpatient basis, and can be
repeated to treat recurrent tumor, laparoscopic and thoraco-
Table 2 Treatment and follow-up.
Number of patients 72
Follow-up duration 162.1 ± 81.0
(36–299) [146.5]
Follow-up sessions Once 26 (36.1%)
Twice 22 (30.6%)
Thrice 24 (33.3%)
Number of nodules 1 46 (63.9%)
2 26 (36.1%)
Size of nodules 3.2 ± 0.9
(2–5) [2.9]
63 58/98 nodule
(59.2%)
>3 40/98 nodule
(41.8%)
MW ablationa
63 Success 57/58 (98.3%)
Failure 1/58 nodule
(1.7%)
>3 Success 37/40 (92.5%)
Failure 3/40 nodule
(7.5%)
Recurrence 11 (15.3%)
a-Fetoprotein
All patients Pre 317.9 ± 235.1
(9–789) [231]
<200 32 (44.4%)
>200 40 (55.6%)
Only patients with >200 pre-operatively 1 m after 117.9 ± 78.1
(10–517) [117]b
<200 39 (97.5%)
>200 1 (2.5%)
4 m after 106.0 ± 47.2
(21–176) [102]b
<200 24 (96.0%)
>200 1 (4.0%)
7 m after 85.8 ± 50.0
(10–165) [82]b,c
<200 14 (100%)
>200 0 (0%)
a P-value = 0.301 for comparison between size groups regarding
success.
b P-value < 0.001 for comparison with pre-ablation.
c P-value = 0.036 for comparison with 4 months follow-up.
Figure 5 a-FP levels pre-ablation and during follow-up.
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tions inaccessible by the percutaneous approach (16).
This study reports the ﬁrst initial utilization of this type of
MW technology in the management of HCC at our institution.
The ablation procedures were performed percutaneously with
HS Amica probe. Percutaneous MWA appeared to be a well
tolerated treatment in our patient group with no post-opera-
tive deaths and no complication occurred related to the abla-
tion procedure. None of the patients in this series showed
evidence of sepsis, bile duct damage, uncontrollable bleeding,
or signiﬁcant systemic upset. This compares very favorably
with studies of alternative ablative modalities which have re-
ported complications in up to 33% of the patients treated
(17,18). Also, the study of Xu et al. (6), reported complications
related to MW ablation in nine patients including pleural effu-
sion in two liver failure in one, hepatic abscess in two, skin
burn in two and sub capsular hematoma in two.
In the present study, by using the cooled-shaft microwave
antenna, and repeated probe re-insertion technique, the com-
plete ablation rates for tumors 3 cm or less and those larger
than 3 cm were 98.3% (57 of 58 nodules) and 92.5% (37 of
40 nodules), respectively. The four incompletely ablated tu-
mors were treated with additional percutaneous MWA ses-
sions and technical success was achieved in all. These results
were comparable to those reported from Lu et al. (10) whose
technical success rates for tumors 2 cm or smaller and those
larger than 2 cm were 98% (45 of 46 nodules) and 92%
(56% of 61 nodules), respectively, and after additional MW
ablation sessions technical success was achieved in all his
incompletely ablated tumors. However, our present results
were quite superior to those of Kung et al. (14) who treated
90 patients with unresectable liver cancers. The complete abla-
tion rates were 94%, 91%, and 92% for small (63 cm), inter-
mediate (3.1–5.0 cm) and large (5.1–8.0 cm) liver cancers.
Additionally, in the study of Xu et al. (6) using multiple elec-
trode insertion technique, the complete ablation rates at
1 month post-ablation in tumors 2.0, 2.1–3.9 and 4.0 cm in
diameter were 93.1%, 93.8%, and 86.4%, respectively.
In our study, 39/40 patients with elevated a-FP showed de-
creased levels to within the normal range one month after abla-
tion, and the remaining patient showed gradual decrease to
reach the normal level at 7 months post-ablation. In the study
of Lu et al. (10), 18/50 patients with elevated a-FP before abla-
tion showed marked decrease at 1 month after MWA. Dong et
al. (9), had in their study 139/234 patients with elevated a-FP
level pre-ablation. At 1 month post-ablation 101/139 had de-
creased a-FP to normal level and 28/139 showed decrease in
a-FP level although it did not drop to normal. The a-FP levels
remained unchanged after MWA in 10 patients.
Though evaluating long term results and survival rates of
percutaneous MWA is beyond our objective in this study,
yet in our limited study period (10 months), the survival rate
was 100%. This compares favorably with study of Lu et al.
(10), where the 1 year survival rate for 36 patients was 96%,
and that of Dong et al. (9), 1 year survival rate for 185 patients
was 92.7%.
Limitation of our study; it was a short limited study and
hence reliable long term results and survival rates could not
be properly evaluated. It is a short term preliminary study fo-
cused on the technical efﬁcacy and safety of this newMW tech-
nology rather than a long term follow-up study. However,
further study with a larger patient sample and longer follow-
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low-up and survival rate study.
5. Conclusion
This study suggests this new MW technology represents a safe,
fast and efﬁcacious way to perform hepatic ablation in patients
with HCC. Initial results are encouraging, however, longer
follow-up is needed for further classiﬁcation of our results.
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